Nitazoxanide dosing: 500 mg tablets twice daily
Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day

Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day

Encephalopathy, Hepatic

• Nitazoxanide dosing: 500 mg tablets twice daily

Nitazoxanide

• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day

Lactulose

Tanta university - faculty of medicine

Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy

A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy

Sherief Abd-Elsalam

sponsor investigator

Tanta University

VSL#3 is a mix of lactic acid bacteria and bifidobacteria (original De Simone's formulation)

HIV Seropositivity

VSL#3 sachets

Policlinico Umberto I Hospital

Effects of VSL#3 on Neuro-cognitive Profile of HIV Patients

Title Effect of Microbial Translocation and Supplementation With the Probiotic VSL#3 on Neuro-cognitive Functions of HIV Positive Patients Receiving HAART

HIV dementia-scale, Beck Depression Inventory BDI-II, State Trait Anxiety Inventory (STAI Y 1 - Y2), the questionnaire for the assessment of quality of life in persons with HIV infection (ISS-QoL)

Dott.ssa Gabriella D'Ettorre

Azienda Policlinico Umberto I

L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days

Placebo (sterile water, 6 ampuoles of 10 ml each) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days

Cirrhosis of Liver

Hepatic Encephalopathy

L-ornithine L-aspartate

Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days

Placebo

Department of Gastroenterology, D.M.C. and Hospital

G.B. Pant Hospital

L-ornithine L-aspartate in Overt Hepatic Encephalopathy

Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial

Mental state grade according to West Haven criteria for Hepatic encephalopathy

Change in blood ammonia levels will be measured at baseline and after 5 days of treatment

Mortality rate in the two groups at 4 weeks will be compared

The total length of hospital stay (number of days) in each group will be compared.

Change in serum cytokine levels (Interleukin-1, Interleukin-6, Interleukin-10 and TNF-alpha will be measured at baseline and after 5 days of treatment.

acetic acid/buinneach

Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy

Effects of VSL#3 on Neuro-cognitive Profile of HIV Patients

L-ornithine L-aspartate in Overt Hepatic Encephalopathy

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht